18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis

July 11, 2022 updated by: Chunjing Yu, Wuxi No. 4 People's Hospital
A total of 11 patients confirmed with tuberculous pericarditis were enrolled in this study to analyze the diagnostic value of 18F-FDG PET/CT for tuberculous pericarditis.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

A total of 11 patients with tuberculous pericarditis, who underwent 18F-FDG PET/CT from January 2015 to February 2022 in the affiliated hospital of Jiangnan university were retrospectively reviewed in this study to analyze the diagnostic value of 18F-FDG PET/CT in tuberculous pericarditis.

Study Type

Observational

Enrollment (Actual)

11

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

48 years to 81 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

A total of 11 patients confirmed with tuberculous pericarditis were enrolled in this study.

Description

Inclusion Criteria:

patients confirmed as tuberculous pericarditis through follow-up.

Exclusion Criteria:

patients confirmed as other pericarditis through follow-up.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
tuberculous pericarditis with 18F-FDG uptake
patients confirmed with tuberculous pericarditis presenting 18F-FDG uptake
Diagnostic test: 18F-FDG
18F-FDG intravenous injection
tuberculous pericarditis without 18F-FDG uptake
patients confirmed with tuberculous pericarditis presenting no 18F-FDG uptake
Diagnostic test: 18F-FDG
18F-FDG intravenous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the diagnostic sensitivity of 18F-FDG PET/CT for tuberculous pericarditis
Time Frame: 01,2015-02,2022
the diagnostic sensitivity of 18F-FDG PET/CT for tuberculous pericarditis
01,2015-02,2022

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Wuxi No. 4 People's Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2015

Primary Completion (ACTUAL)

February 28, 2022

Study Completion (ACTUAL)

February 28, 2022

Study Registration Dates

First Submitted

July 11, 2022

First Submitted That Met QC Criteria

July 11, 2022

First Posted (ACTUAL)

July 14, 2022

Study Record Updates

Last Update Posted (ACTUAL)

July 14, 2022

Last Update Submitted That Met QC Criteria

July 11, 2022

Last Verified

July 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Wuxi4PH-2022-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diagnostic Self Evaluation

Clinical Trials on 18F-FDG

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe